Clinical Trials
23 trialsNCT06192004 2026-05-04
LOOP
AstraZeneca
Terminated
NCT05257551 2026-04-02
TEMPUS Small Cell Lung Cancer OBSERVATIONAL STUDY (Sculptor)
Tempus AI
Recruiting
NCT05236114 2026-02-05
GEMINI-NSCLC: NSCLC Biomarker Study
Tempus AI
Recruiting
NCT06887348 2026-01-12
RPx
Replimune, Inc.
Recruiting
NCT04770571 2025-12-22
Posterior Cervical Fixation Study
Globus Medical Inc
Enrolling by invitation
NCT05323747 2025-09-16
BP-008
BioProtect
Completed
NCT05354427 2025-09-16
CLP-10095
BioProtect
Completed
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT05234177 2025-05-06
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
Tempus AI
Recruiting
NCT04528407 2025-02-13
BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects
BlueSky Immunotherapies GmbH
Completed
NCT06008353 2024-12-19
EDUR-BRA
AstraZeneca
Active not recruiting
NCT05592483 2024-11-07
DB RESPOND
AstraZeneca
Terminated
NCT05775549 2024-09-20
FLAME
AstraZeneca
Completed
NCT06126003 2024-08-02
Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.
BioCorteX Inc
Terminated
NCT04566432 2024-07-18
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients
Geneplus-Beijing Co. Ltd.
Recruiting
NCT04857619 2024-07-11
Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer
AstraZeneca
Completed
NCT04060290 2024-02-28
Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Completed
NCT05292443 2024-02-23
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
Geneplus-Beijing Co. Ltd.
Withdrawn
NCT02733601 2023-04-03
BreCaReAl
AstraZeneca
Completed
NCT04807595 2023-03-06
Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status
AstraZeneca
Completed
NCT05032352 2022-11-14
PADMA
Insight Molecular Diagnostics
Terminated
NCT05423431 2022-06-24
Retrospective Evaluation of a Commercially Available Hydrogel Spacer (BP-009)
BioProtect
Completed
NCT00754000 2012-04-30
AIM
Varian, a Siemens Healthineers Company
Completed